Literature DB >> 24927668

Nanoparticle ligand presentation for targeting solid tumors.

Jason T Duskey1, Kevin G Rice.   

Abstract

Among the many scientific advances to come from the study of nanoscience, the development of ligand-targeted nanoparticles to eliminate solid tumors is predicted to have a major impact on human health. There are many reports describing novel designs and testing of targeted nanoparticles to treat cancer. While the principles of the technology are well demonstrated in controlled lab experiments, there are still many hurdles to overcome for the science to mature into truly efficacious targeted nanoparticles that join the arsenal of agents currently used to treat cancer in humans. One of these hurdles is overcoming unwanted biodistribution to the liver while maximizing delivery to the tumor. This almost certainly requires advances in both nanoparticle stealth technology and targeting. Currently, it continues to be a challenge to control the loading of ligands onto polyethylene glycol (PEG) to achieve maximal targeting. Nanoparticle cellular uptake and subcellular targeting of genes and siRNA also remain a challenge. This review examines the types of ligands that have been most often used to target nanoparticles to solid tumors. As the science matures over the coming decade, careful control over ligand presentation on nanoparticles of precise size, shape, and charge will likely play a major role in achieving success.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927668      PMCID: PMC4179653          DOI: 10.1208/s12249-014-0143-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  150 in total

1.  Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier.

Authors:  Yutaka Miura; Tomoya Takenaka; Kazuko Toh; Shourong Wu; Hiroshi Nishihara; Mitsunobu R Kano; Yasushi Ino; Takahiro Nomoto; Yu Matsumoto; Hiroyuki Koyama; Horacio Cabral; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  ACS Nano       Date:  2013-09-18       Impact factor: 15.881

2.  Real-time evaluation of binding mechanisms in multivalent interactions: a surface plasmon resonance kinetic approach.

Authors:  Eva Maria Munoz; Juan Correa; Ricardo Riguera; Eduardo Fernandez-Megia
Journal:  J Am Chem Soc       Date:  2013-04-12       Impact factor: 15.419

Review 3.  Rationale for the use of somatostatin analogs as antitumor agents.

Authors:  C Susini; L Buscail
Journal:  Ann Oncol       Date:  2006-06-26       Impact factor: 32.976

4.  High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy.

Authors:  M C Frühwald; M S O'Dorisio; T Pietsch; J C Reubi
Journal:  Pediatr Res       Date:  1999-05       Impact factor: 3.756

5.  Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.

Authors:  L J Hofland; P M van Koetsveld; M Waaijers; J Zuyderwijk; W A Breeman; S W Lamberts
Journal:  Endocrinology       Date:  1995-09       Impact factor: 4.736

6.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

Review 7.  Clinical value of drugs targeting inflammation for the management of coronary artery disease.

Authors:  Valérie Duchatelle; Ekaterini A Kritikou; Jean-Claude Tardif
Journal:  Can J Cardiol       Date:  2012-08-24       Impact factor: 5.223

8.  Does a targeting ligand influence nanoparticle tumor localization or uptake?

Authors:  Kathleen F Pirollo; Esther H Chang
Journal:  Trends Biotechnol       Date:  2008-08-21       Impact factor: 19.536

9.  Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma.

Authors:  M S O'Dorisio; D J Fleshman; S J Qualman; T M O'Dorisio
Journal:  Regul Pept       Date:  1992-02-18

10.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

View more
  6 in total

1.  Translational application of nano delivery systems: emerging cancer therapy.

Authors:  Mahavir B Chougule; Chalet Tan
Journal:  AAPS PharmSciTech       Date:  2014-12-31       Impact factor: 3.246

2.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Authors:  Helen Lee; Anthony F Shields; Barry A Siegel; Kathy D Miller; Ian Krop; Cynthia X Ma; Patricia M LoRusso; Pamela N Munster; Karen Campbell; Daniel F Gaddy; Shannon C Leonard; Elena Geretti; Stephanie J Blocker; Dmitri B Kirpotin; Victor Moyo; Thomas J Wickham; Bart S Hendriks
Journal:  Clin Cancer Res       Date:  2017-03-15       Impact factor: 12.531

Review 3.  Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines.

Authors:  Riya Khetan; Cintya Dharmayanti; Todd A Gillam; Eric Kübler; Manuela Klingler-Hoffmann; Carmela Ricciardelli; Martin K Oehler; Anton Blencowe; Sanjay Garg; Hugo Albrecht
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

4.  The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles.

Authors:  Jing Wang; Michael Dzuricky; Ashutosh Chilkoti
Journal:  Nano Lett       Date:  2017-09-05       Impact factor: 11.189

Review 5.  Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy.

Authors:  Aiying Xue; Saijun Fan
Journal:  Biomolecules       Date:  2022-06-12

Review 6.  Solid-phase supported design of carriers for therapeutic nucleic acid delivery.

Authors:  Ana Krhac Levacic; Stephan Morys; Ernst Wagner
Journal:  Biosci Rep       Date:  2017-10-31       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.